Key Highlights

  • IQVIA (NYSE:IQV) is scheduled to report third-quarter 2026 results before the open on Tuesday, October 27, 2026, with consensus adjusted earnings of USD 3.28 per share.
  • Second-quarter adjusted earnings of USD 3.15 per share rose 12.1% on revenue of USD 4.37 billion, and management said results exceeded the high end of its expectations for revenue, EBITDA and earnings.
  • Full-year guidance was raised to revenue of USD 17.275 billion to USD 17.475 billion, adjusted EBITDA of USD 4.00 billion to USD 4.05 billion and adjusted earnings of USD 12.80 to USD 13.00 per share.
  • Net new bookings of USD 3.15 billion in the research and development segment gave a book-to-bill ratio of 1.22 times, so conversion of a USD 34.2 billion backlog is the central test.

The Setup Against Last Quarter's Guidance

IQVIA (NYSE:IQV) provides clinical trial services, health data and analytics to drug developers, and it is scheduled to report third-quarter 2026 results before the open on Tuesday, October 27, 2026, according to the company's announcement of September 2026. Consensus adjusted earnings are USD 3.28 per share, USD 0.13 above the USD 3.15 reported for the second quarter. That quarter brought revenue of USD 4.368 billion, up 8.7% year on year, and adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) of USD 994 million, up 9.2%. Full-year guidance was raised to adjusted earnings of USD 12.80 to USD 13.00 per share. Results cannot be known in advance.

How Bookings and Backlog Drive the Reaction

The research and development segment, which runs trials for drug sponsors, produced revenue of USD 2.575 billion, up 8.8%, with organic growth of 7%. Net new bookings rose 19% to USD 3.15 billion, a book-to-bill ratio of 1.22 times, meaning contracts signed exceeded revenue recognised. Contracted backlog stood at USD 34.2 billion, and about USD 9.2 billion is expected to convert to revenue over the next twelve months. Commercial Solutions, which sells data and sales support to drug makers, produced USD 1.793 billion, up 8.6%. The chief executive cited double-digit growth in patient solutions and commercial engagement services and expected sustained momentum for the rest of the year and into 2027, which sets a high bar for the cancellation rate and conversion pace.

Risks and What to Watch

The bull case is bookings that keep the book-to-bill ratio above 1.2 times, revenue growth near 8% and a guidance range that is raised again toward the upper end of USD 12.80 to USD 13.00, which would likely support the shares because backlog visibility underpins the valuation. The bear case is a rise in contract cancellations, slower conversion of backlog or tighter biotech funding, any of which could prompt a sharp fall in a stock priced for steady compounding. Pricing in competitive tenders is a longer-term question. Investors should watch the cancellation rate and the second-half revenue conversion. The Federal Reserve decides on Wednesday, October 28, 2026, after raising rates on Wednesday, September 16, 2026 to a range of 3.75% to 4.00%.

Where Things Stand

The answer is that IQVIA (NYSE:IQV) faces a bar of USD 3.28 that follows from its second-quarter beat and a raised full-year range, so a modest beat and a stable outlook are probably needed. Backlog quality matters more than a single quarter. The next catalysts are the results before the open on Tuesday, October 27, 2026, the Federal Reserve decision on Wednesday, October 28, 2026 and the management call that discusses third-quarter and full-year guidance. Estimates and guidance are not guarantees, and this is not investment advice.